Kestra Medical Technologies
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 months.
- Recent price momentum is -3.7% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 6.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 51.4% | Better than 65% |
| Operating margin | -141.6% | Better than 6% |
| Net margin | -138.4% | Better than 6% |
| Return on equity | -56.6% | Better than 8% |
| Return on invested capital | -47.5% | Better than 6% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -7.0% | Better than 57% |
| 6-month return | 16.0% | Better than 79% |
| 12-month return (ex latest month) | 8.5% | Better than 44% |
| Distance below 52-week high | 21.5% | Better than 57% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.4x | Better than 83% |
| Debt to assets | 13.1% | Better than 65% |
| Interest coverage | -16.4x | Better than 11% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 21.9% | Better than 36% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 26.63
- Open
- 26.14
- Day range
- 24.94 - 27.50
- Avg price
- 25.64
- Volume
- 435.08K
- Turnover
- 11.15M
- Turnover ratei
- 1.41%
- Volume ratioi
- 1.23
- Amplitudei
- 9.59%
- 52-week rangei
- 17.34 - 31.99
Valuation
- P/Ei
- -10.33
- P/E (TTM)i
- -9.92
- P/Bi
- 6.72
- EPSi
- -2.43
- Book value / shi
- 3.73
- Net profit
- -144.74M
- Net assets
- 222.34M
Share structure
- Market cap
- 1.50B
- Float capi
- 773.66M
- Shares out
- 59.56M
- Float sharesi
- 30.82M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2025-03-06
21.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+7.48M net over the window
Short interest
- Shares short
- 4.10M
- % of floati
- 6.89%
- Days to coveri
- 8.15
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Kestra Medical Technologies (KMTS)?
Kestra Medical Technologies last traded at 25.10. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Kestra Medical Technologies's market cap?
About 1.50B.
What is the P/E ratio of Kestra Medical Technologies?
The trailing twelve-month P/E is -9.92. The Valuation tab shows it against the stock's own five-year range.
Does Kestra Medical Technologies pay a dividend?
Kestra Medical Technologies does not currently pay a regular dividend.
Is Kestra Medical Technologies a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 30.60, which implies 21.9% upside from the current price. This is not investment advice.
What is Kestra Medical Technologies's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Kestra Medical Technologies a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Kestra Medical Technologies discussion 0 comments